Telix Pharmaceuticals (NASDAQ:TLX) Issues Quarterly Earnings Results

Telix Pharmaceuticals (NASDAQ:TLX) released its quarterly earnings results on Thursday. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.01, FiscalAI reports. The business had revenue of $238.50 million for the quarter, compared to the consensus estimate of $479.63 million.

Telix Pharmaceuticals Price Performance

NASDAQ:TLX opened at $12.12 on Thursday. The firm’s fifty day moving average is $10.87 and its 200-day moving average is $9.60. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. Telix Pharmaceuticals has a 52 week low of $6.28 and a 52 week high of $12.60.

Analysts Set New Price Targets

Several brokerages recently weighed in on TLX. Citigroup reissued a “buy” rating on shares of Telix Pharmaceuticals in a research note on Thursday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Friday, July 17th. Wedbush reaffirmed an “outperform” rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a report on Monday, July 6th. Royal Bank Of Canada lowered Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a research report on Friday, July 17th. Finally, HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a research report on Tuesday, July 7th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Telix Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.40.

Hedge Funds Weigh In On Telix Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Millennium Management LLC acquired a new stake in Telix Pharmaceuticals during the 3rd quarter worth about $1,883,000. Portland Investment Counsel Inc. lifted its stake in shares of Telix Pharmaceuticals by 108.0% in the 4th quarter. Portland Investment Counsel Inc. now owns 266,200 shares of the company’s stock valued at $2,063,000 after purchasing an additional 138,200 shares during the period. Lazard Asset Management LLC lifted its stake in shares of Telix Pharmaceuticals by 118.6% in the 4th quarter. Lazard Asset Management LLC now owns 250,517 shares of the company’s stock valued at $1,876,000 after purchasing an additional 135,893 shares during the period. Russell Investments Group Ltd. bought a new stake in shares of Telix Pharmaceuticals during the 2nd quarter valued at about $975,000. Finally, Quadrature Capital Ltd bought a new stake in shares of Telix Pharmaceuticals during the 4th quarter valued at about $276,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.